医疗技术公司波士顿科学周一宣布，已同意以3.6亿美元的初始价格收购私营医疗设备公司SoniVie的剩余部分股份，以扩大公司在介入心脏病学疗法的产品组合。

　　波士顿科学公司目前已经拥有SoniVie公司10%股份。该公司表示，预计将在2025年上半年完成收购交易，在达到监管里程碑后，它可能会额外支付高达1.8亿美元。

　　波士顿科学公司表示，SoniVie开发了研究性Tivus血管内超声系统，旨在对血管周围的神经进行去神经支配，以治疗各种高血压疾病，包括因高血压而进行肾动脉去神经支配。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.